This medication is applied in addressing certain distressing symptoms across multiple neurological and psychiatric domains. It is relevant in contexts marked by increased discomfort or tension, where additional symptomatic support is needed. It may be part of symptomatic management for conditions including chronic neuropathic pain (such as diabetic neuropathy, postherpetic neuralgia, or spinal cord injury-related pain), as an adjunct for partial-onset seizures in epilepsy, and in the management of Generalized Anxiety Disorder (GAD) and Fibromyalgia.

“The intent of this supportive relief is to help patients cope more steadily with symptom fluctuations and support general well-being during symptomatic phases.”

This medication may assist with managing symptoms that create noticeable functional strain, such as the persistent burning and shooting pain that interferes with daily functioning, or the symptoms related to heightened physiological activity and tension, such as those associated with GAD. This supportive relief may contribute to easing the overall symptom load and supports the patient during difficult episodes by easing distress.

Quick Fact: Symptomatic Support
This medication is commonly used to help with symptoms related to neurological or muscular activity, specifically the sharp, chronic stabbing or burning pain that interferes with daily functioning.

Regulatory References

1. NIH MedlinePlus overview

Eligibility for Pregabalina Stada Genericos: Official Regulatory Information

The eligibility profile for Pregabalin is defined by specific population groups, organ function status, and reproductive considerations, as mandated by regulatory authorities.

Contraindicated Populations:

• Patients with Hypersensitivity: Individuals with a known hypersensitivity to the active substance pregabalin or to any of the product's excipients are prohibited from use.

Age-Related Eligibility:

• Adults (17 years and older): Constitute the standard eligible population for all approved indications.
• Pediatric Patients (1 month and older): Use is established for the adjunctive treatment of partial-onset seizures.
• Children/Adolescents (<18 years): Safety and efficacy are not established for indications other than partial-onset seizures.
• Older Adults (>65 years): Eligible, but may require dose adjustment due to age-related changes in renal function.

Conditional Use and Restrictions:

• Renal Impairment: Because the medicine is eliminated by the kidneys, a mandatory dose reduction is required for patients with reduced renal function, based on their creatinine clearance.
• Pregnancy and Lactation: Use during pregnancy is not recommended due to potential risks, and women of childbearing potential must use effective contraception. Use while breastfeeding is not recommended as the substance is present in breast milk.
• Comorbidities: Use requires caution in patients with a history of substance abuse or compromised respiratory function.

---

Resulting Eligibility Structure

Official regulatory documents establish that the medicine is contraindicated only by known hypersensitivity. All other limitations define conditional eligibility, primarily driven by the need to adjust the dose based on CLcr (renal function) or by reproductive status, which is officially classified as not recommended for use.

Pregabalin's interaction profile, as defined by official regulatory documents, is predominantly characterized by pharmacodynamic risk rather than metabolic concern.

Pharmacodynamic Interactions

Co-administration with Central Nervous System (CNS) depressants (including opioids, benzodiazepines, and certain antihistamines) creates an additive effect that increases the risk of dizziness, somnolence, and potentially severe respiratory depression. The use of alcohol is officially restricted due to this additive effect, which potentiates motor skill impairment and sedation. Furthermore, co-administration with Opioid Analgesics has been associated with reduced lower gastrointestinal tract function, increasing risks such as paralytic ileus.

Other Clinically Significant Interactions

Official documentation cautions regarding combinations with specific drug classes:

• Thiazolidinedione Antidiabetic Agents (e.g., pioglitazone) increase the risk of developing peripheral edema and weight gain.
• Angiotensin-Converting Enzyme (ACE) Inhibitors are associated with an increased risk of angioedema (swelling).

Pharmacokinetic and Timing Profile

Pregabalin exhibits a simplified pharmacokinetic profile, as it is negligibly metabolized and does not inhibit or induce the CYP450 enzyme system. Consequently, no significant pharmacokinetic interactions are documented with common antiepileptic drugs. The immediate-release capsule and oral solution forms may be taken with or without food, as meals do not alter the total amount of drug absorbed. Since Pregabalin is primarily eliminated by renal excretion, interaction-related severity is officially noted as heightened in the elderly population and patients with renal impairment.

How Pregabalina Stada Genericos Works

Pregabalina (Pregabalin) acts by binding to the alpha-2-delta (alpha2delta) auxiliary subunit of presynaptic Voltage-Gated Calcium Channels (VGCCs) in the central nervous system. This molecular interaction functionally modulates the channel complex, leading to a reduction in the influx of calcium ions (Ca^2+) into the nerve terminal upon neuronal activation.

The physiological consequence of reduced calcium influx is a direct decrease in the release of key excitatory neurotransmitters, such as Glutamate and Substance P, into the synaptic cleft. This reduction of chemical signaling between nerves occurs primarily in neuronal networks characterized by pathological hyperexcitation.

By reducing excitatory chemical signal transmission across hyperactive pathways, the mechanism results in a decreased rate of nerve impulse propagation. This localized action produces a system-level effect of modulated neuronal excitability, characterized by rebalanced signaling within pathologically hyperactive neuronal networks.

The administration of Pregabalin is governed by official protocols designed to manage dose changes systematically, establishing a standardized approach to usage. The medicine is prescribed exclusively for oral intake, available in immediate-release capsules and an oral solution. Its administration is flexible regarding food, as it may be taken with or without meals. The total quantity administered daily typically ranges from 150 mg to 600 mg. This daily amount must be divided and consumed in either two (BID) or three (TID) separate doses to ensure consistent delivery of the substance.

Initiating treatment or increasing the daily amount requires a gradual process (titration). Similarly, if the medicine is to be stopped, the dose must be tapered gradually over a minimum period of one week to conclude the course of use. The official guidelines strictly stipulate that the patient's renal function determines the correct dosage. Adjustments are mandatory for adults with impaired kidney function, and those on hemodialysis require a supplementary single dose immediately following the 4-hour treatment.

If the oral solution is used, an accurate measuring device, not a standard household spoon, must be utilized for precise dosing. If a scheduled dose is inadvertently missed, patients are instructed not to take a double dose to make up the difference, but should resume the planned schedule at the next designated time.

Research Evidence / Overview of Studies for Pregabalina Stada Genericos

Evidence for Use in Managing Neuropathic Pain

Research explored how this medicine was studied for certain types of chronic nerve pain, including pain associated with diabetic neuropathy, postherpetic neuralgia, and spinal cord injury. Studies primarily used short-term, placebo-controlled clinical trials focusing on adults. These trials monitored outcomes related to physical discomfort, measured through daily patient reports of pain intensity and sleep interference measures.

The findings describe patterns observed in the studies related to the measurement of pain scores from baseline, compared to those receiving placebo. Research highlights changes measured during the study period, including patient-reported outcomes describing perceived discomfort. Existing studies provide limited insight into long-term outcomes beyond the few months covered by the primary Randomized Controlled Trials (RCTs).

---

Evidence for Use in Treating Generalized Anxiety Disorder (GAD)

Research explored the medicine’s use in adult populations with Generalized Anxiety Disorder (GAD), which are conditions characterized by fluctuating or episodic manifestations of tension and worry. Studies focused on outcomes related to physiological strain or stress, using standardized scales to measure the reported severity of both mental and physical anxiety symptoms.

Findings describe patterns observed in the studies, showing differences recorded in total anxiety scores compared to control groups. Long-term studies monitored patients for up to six months or more to assess patterns related to the maintenance of the observed effects. The medication was not consistently studied in direct comparison trials against certain newer classes of commonly prescribed anxiolytics.

---

Research Gaps and Areas of Scientific Uncertainty

Important research is ongoing and key limitations remain. The short follow-up durations were limited in the core trials for all indications. As a result, there is limited information for long-term outcomes and the durability of any observed changes. The comparative evidence is lacking for many direct head-to-head comparisons against other commonly used therapies. While the evidence highlights what is known, the research does not allow for individual predictions regarding response, as the study results reflect the specific conditions under which they were conducted.

Common questions about Pregabalina Stada Genericos (FAQ)

Q: Is Pregabalina Stada Genericos the same kind of medicine as Gabapentin?

Official information indicates that Pregabalin, the active substance, belongs to the same class of medicines as Gabapentin, called Gabapentinoids. They are both described as having a similar mechanism of action, meaning they work in comparable ways in the nervous system. Regulatory findings describe distinct chemical structures and differences in their absorption characteristics.

---

Q: How quickly should I expect to feel an effect after starting this drug?

Studies and official information describe that while the medicine is rapidly absorbed, the observed symptom changes were typically measured over a period of 1 to 2 weeks of consistent treatment. For conditions such as neuropathic pain, the full effect was typically observed in clinical trials developing over one to two weeks of continuous use.

---

Q: How long does a dose of Pregabalina Stada Genericos stay active in the body?

According to official pharmacokinetic information, the elimination half-life of Pregabalin is approximately 6.3 hours in people with normal kidney function. This means it takes about 6.3 hours for half of the substance to be cleared from the system. Since the substance is primarily eliminated by the kidneys, its measured clearance is consistent with the majority of the substance being cleared within about 32 to 35 hours.

---

Q: What are the rules regarding driving or operating machinery while on this drug?

Official regulatory documents include warnings that this medicine may impair the ability to drive or operate machinery due to the risk of dizziness and somnolence (drowsiness). The warning advises caution regarding these activities until the individual response to the medication is known.

---

Q: Can Pregabalina Stada Genericos cause mood changes or depression?

Official product information notes that psychiatric adverse reactions, including confusion and euphoric mood, have been reported. Furthermore, regulatory labels warn of the risk of suicidal thoughts or behavior. Due to this risk, official regulatory documents indicate that monitoring for new or worsening depression and changes in behavior or mood is required during treatment.

---

Q: What is the official classification of this drug (e.g., controlled substance)?

Pregabalina Stada Genericos is classified as a prescription-only medicine in all regulatory regions. In the United States, it is designated as a Schedule V controlled substance, and regulatory status may vary by country.

---

Q: Does Pregabalina Stada Genericos interact with herbal supplements like St. John's Wort?

Official information cautions against combining this medicine with other substances that depress the Central Nervous System (CNS). Since the medicine is classified as a CNS depressant, this may result in increased adverse reactions like dizziness or difficulty concentrating. Regulatory documents do not provide specific interaction studies for herbal supplements.

---

Q: Are there different strengths of Pregabalina Stada Genericos capsules available?

Yes, regulatory documents confirm that the medicine is offered in a wide range of capsule strengths. These typically include 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg capsules. The various available strengths are designed to allow for appropriate dose adjustment as needed.

---

Q: What kind of monitoring (e.g., blood tests) might be needed while taking this drug?

Official regulatory documents indicate that monitoring is required for specific adverse events. This includes watching for signs of weight gain, peripheral swelling (oedema), and respiratory difficulties. Additionally, patients are monitored for changes in mood or behavior due to the noted risk of suicidal ideation.

---

Q: Can Pregabalina Stada Genericos affect blood pressure?

Clinical trial data included in official documents reports that changes in blood pressure have occurred in some patients. Both low blood pressure (hypotension) and high blood pressure (hypertension) have been reported as possible adverse reactions, though these often occur at an uncommon frequency.

---

Q: What should I do if I accidentally take more than the amount prescribed?

Official overdose information notes that symptoms of taking too much can include confusion, agitation, somnolence, and in very rare cases, coma. Official regulatory information on overdosage states that patients should seek immediate medical attention, contacting a poison control center or emergency services.

---

Q: Is the main difference between Pregabalina and Gabapentin the way they are absorbed?

Pharmacokinetic data indicates that there is a difference in the absorption profile between the two Gabapentinoids. Official information indicates that Pregabalin’s absorption is not limited by dose size, allowing for proportional uptake.

---

Q: Is this medicine known to affect vision?

Official regulatory safety data lists blurred vision as a commonly reported side effect. Visual adverse reactions, which include changes in visual acuity and, rarely, severe vision problems, have been reported in post-market experience. These visual changes may be temporary.

---

Q: What does the term 'peripheral neuropathic pain' mean in simple language?

According to patient information leaflets and educational materials, this is the term used for pain caused by damage to the nerves outside of the brain and spinal cord. Patient information leaflets often describe this pain as a burning, shooting, or tingling sensation that occurs primarily in the extremities, such as the hands or feet.

Storage and Disposal of Pregabalina Stada Genericos

Official regulatory documents define specific conditions for storing and disposing of this medication.

Storage Requirements

This medicine generally does not require special temperature conditions but should be stored at room temperature, away from excess heat and in a location protected from light and moisture. The product must be kept in its original container, which should remain tightly closed to preserve quality. As a mandatory safety requirement, the medicine must be stored out of the sight and reach of children.

Disposal Instructions

To prevent environmental contamination, unused or expired Pregabalina Stada Genericos must not be thrown away in household trash or poured down the drain. The official method for disposal is to return the product to a collection point, such as a pharmacy's drug take-back program. You should ask your pharmacist for guidance on the proper disposal of the medicinal product and its packaging.